{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:42Z","timestamp":1780549542485,"version":"3.54.1"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Dyslipidemia, a key risk factor for atherosclerotic cardiovascular disease (ASCVD), is conventionally managed by lowering low-density lipoprotein cholesterol (LDL-C) level. However, even with on-target LDL-C and optimal control of traditional risk factors such as hypertension and diabetes, a substantial residual risk of major adverse cardiovascular events (MACE) persists. A growing body of evidence suggests that remnant cholesterol (RC) \u2013 the cholesterol content of triglyceride-rich lipoproteins (TRLs) \u2013 partially contributes to this residual risk. Consequently, non-high-density lipoprotein cholesterol (non-HDL-C) is considered a better measure of the ASCVD risk and a comprehensive treatment goal for dyslipidemia. Statin therapy, the standard care for dyslipidemia management, falls short of mitigating RC-related residual risk. The global rise in obesity, type 2 diabetes, and metabolic syndrome has led to a growing prevalence of hypertriglyceridemia, underscoring the need for adjunctive therapies that target TRLs and lower non-HDL-C levels. Fenofibrate, a well-established TRL-lowering agent, has demonstrated efficacy in reducing non-HDL-C when used in combination with statins. Evidence from clinical trials and real-world studies suggests potential benefits of this combination in reducing cardiovascular risk, particularly in patients with elevated triglyceride levels. Moreover, long-term studies \u2013 spanning up to two decades \u2013have affirmed the safety and tolerability of fenofibrate, reinforcing its role as a valuable add-on therapy to address remnant cholesterol and residual cardiovascular risk.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1837004","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:30:38Z","timestamp":1780547438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing remnant cholesterol: role of fenofibrate\u2013statin therapy in reducing triglyceride-rich lipoproteins"],"prefix":"10.3389","volume":"13","author":[{"given":"Vikrama","family":"Raja","sequence":"first","affiliation":[{"name":"Medical Affairs, Abbott Products Operations AG","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Santa Cruz, Western Lisbon Local Health Unit","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Alsayed","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes & Metabolism, Dar Alsaha Medical Center","place":["Manama, Kingdom of Bahrain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogeyaa S.","family":"Chibber","sequence":"additional","affiliation":[{"name":"Medical Affairs, WNS Global Services","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"ElBadawi","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Wayne State University","place":["Detroit, MI, U.S.A."]},{"name":"Metabolic Unit, My Clinic International","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Bourgogne Europe, PEC2 UR 7460","place":["Dijon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumari","family":"Pushpa","sequence":"additional","affiliation":[{"name":"Medical Affairs, WNS Global Services","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zoglu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University","place":["Ankara, Turkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Berrou","sequence":"additional","affiliation":[{"name":"Medical Affairs, Abbott Products Operations AG","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P.","family":"Hermans","sequence":"additional","affiliation":[{"name":"P\u00f4le de Recherche Cardiovasculaire, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/heartjnl-2023-322928","article-title":"Atherosclerotic cardiovascular disease risk prediction: current state-of-the-art","volume":"110","author":"Rout","year":"2024","journal-title":"Heart"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e38754","DOI":"10.1097\/MD.0000000000038754","article-title":"A significant presence in atherosclerotic cardiovascular disease: remnant cholesterol: a review","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.7326\/M19-0365","article-title":"Guideline writing committee for the cholesterol G. 2018 cholesterol clinical practice guidelines: synopsis of the 2018 American Heart Association\/American College of Cardiology\/multisociety cholesterol guideline","volume":"170","author":"Grundy","year":"2019","journal-title":"Ann Intern Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25985","DOI":"10.31083\/RCM25985","article-title":"Remnant cholesterol and residual risk of atherosclerotic cardiovascular disease","volume":"26","author":"Li","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"117312","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/eurheartj\/ehac783","article-title":"What is \u2018remnant cholesterol'?","volume":"44","author":"Sturzebecher","year":"2023","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstrom","year":"2022","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Castaner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27038","DOI":"10.1038\/s41598-024-78610-0","article-title":"Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample Mendelian randomization study","volume":"14","author":"Zhong","year":"2024","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1512662","DOI":"10.3389\/fphar.2025.1512662","article-title":"The relationship between remnant cholesterol and young-onset myocardial infarction in patients with type 2 diabetes: a retrospective study","volume":"16","author":"Gao","year":"2025","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson heart and framingham offspring cohort studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e905-e14","DOI":"10.1016\/j.jacl.2024.07.005","article-title":"Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: a post hoc analysis of the RACING trial","volume":"18","author":"Lee","year":"2024","journal-title":"J Clin Lipidol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2011.04.040","article-title":"Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals","volume":"218","author":"Nakamura","year":"2011","journal-title":"Atherosclerosis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1253\/circj.CJ-14-0380","article-title":"High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome","volume":"78","author":"Nguyen","year":"2014","journal-title":"Circ J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/2047487319887578","article-title":"Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease","volume":"27","author":"Elshazly","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e37173","DOI":"10.1097\/MD.0000000000037173","article-title":"Heterogeneity of diabetic dyslipidemia, data from the NHANES (2011\u20132016)","volume":"103","author":"Li","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.2147\/DMSO.S458233","article-title":"Association of biomarkers for dyslipidemia, inflammation, and oxidative stress with endothelial dysfunction in obese youths: a case-control study","volume":"17","author":"Sharma","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/met.2014.0049","article-title":"Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?","volume":"13","author":"Halcox","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"B28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijcard.2017.05.059","article-title":"Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment: expert\u2019s position paper made by the Latin American academy for the study of lipids (ALALIP) endorsed by the inter-American society of cardiology (IASC), the south American society of cardiology (SSC), the pan-American college of endothelium (PACE), and the international atherosclerosis society (IAS)","volume":"243","author":"Ponte-Negretti","year":"2017","journal-title":". Int J Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2174\/157340310791162686","article-title":"Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis from FIELD","volume":"6","author":"Hermans","year":"2010","journal-title":"Curr Cardiol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e70005","DOI":"10.1002\/dmrr.70005","article-title":"One in five atherosclerotic cardiovascular disease events in individuals with diabetes attributed to elevated remnant cholesterol","volume":"40","author":"Wadstrom","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on Major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1490953","DOI":"10.3389\/fnut.2024.1490953","article-title":"Unraveling the discrepancies between REDUCE-IT and STRENGTH trials with omega-3 fatty acids: new analytical approaches","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Nutr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid (RESPECT-EPA)","volume":"150","author":"Miyauchi","year":"2024","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11207690-000000000-00000","article-title":"Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus","volume":"11","author":"Keating","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"B45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.17305\/bb.2022.8534","article-title":"Anti-inflammatory role of fenofibrate in treating diseases","volume":"23","author":"Jin","year":"2023","journal-title":"Biomol Biomed"},{"key":"B46","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1210\/jc.2009-1487","article-title":"Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome","volume":"95","author":"Belfort","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1475-2840-9-24","article-title":"If it ain't broke, don't fix it\": a commentary on the positive-negative results of the ACCORD lipid study","volume":"9","author":"Tenenbaum","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MOL.0b013e328341a5a8","article-title":"Role of fibrates in cardiovascular disease prevention, the ACCORD-lipid perspective","volume":"22","author":"Elam","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"34L","DOI":"10.1016\/j.amjcard.2008.09.073","article-title":"After the fenofibrate intervention and event lowering in diabetes (FIELD) study: implications for fenofibrate","volume":"102","author":"Sacks","year":"2008","journal-title":"Am J Cardiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes","volume":"2","author":"Elam","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-020-01002-x","article-title":"Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study","volume":"19","author":"Zhu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"l5125","DOI":"10.1136\/bmj.l5125","article-title":"Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study","volume":"366","author":"Kim","year":"2019","journal-title":"Br Med J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-024-02353-5","article-title":"Fenofibrate\u2019s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study","volume":"23","author":"Hong","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"155327","DOI":"10.1016\/j.metabol.2022.155327","article-title":"Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels","volume":"137","author":"Kim","year":"2022","journal-title":"Metab Clin Exp"},{"key":"B59","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ehjcvp\/pvad090","article-title":"Associations of omega-3 fatty acids vs. Fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study","volume":"10","author":"Kim","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"117556","DOI":"10.1016\/j.atherosclerosis.2024.117556","article-title":"Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial","volume":"393","author":"Doi","year":"2024","journal-title":"Atherosclerosis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/1570161117666190502103733","article-title":"Microvascular complications of type 2 diabetes Mellitus","volume":"18","author":"Faselis","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"101428","DOI":"10.1016\/j.diabet.2023.101428","article-title":"Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: a propensity-matched cohort study","volume":"49","author":"Kim","year":"2023","journal-title":"Diabetes Metab"},{"key":"B66","doi-asserted-by":"publisher","first-page":"EVIDoa2400179","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of fenofibrate on progression of diabetic retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid"},{"key":"B67","doi-asserted-by":"publisher","first-page":"422","DOI":"10.22608\/APO.2018288","article-title":"Fenofibrate for diabetic retinopathy","volume":"7","author":"Stewart","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the diabetes atherosclerosis intervention study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14656566.2016.1195811","article-title":"Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review","volume":"17","author":"Czupryniak","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000174488","article-title":"Safety of fenofibrate\u2013US and worldwide experience","volume":"76","author":"Roberts","year":"1989","journal-title":"Cardiology"},{"key":"B71","first-page":"5291","article-title":"Comparison of the safety of statin monotherapy and coadministration with fenofibrate in patients with mixed hyperlipidemia: a meta-analysis","volume-title":"Int J Clin Exp Med","author":"Shao","year":"2016"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.amjcard.2012.06.050","article-title":"Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia","volume":"110","author":"Guo","year":"2012","journal-title":"Am J Cardiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1524-6175.2005.05278.x","article-title":"Fibrates in combination with statins in the management of dyslipidemia","volume":"8","author":"Jacobson","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40265-018-0965-8","article-title":"Fenofibrate and dyslipidemia: still a place in therapy?","volume":"78","author":"Tarantino","year":"2018","journal-title":"Drugs"},{"key":"B75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/VHRM.S95044","article-title":"Fenofibrate\/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy","volume":"13","author":"Tarantino","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2215\/CJN.06200518","article-title":"Long-Term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes","volume":"13","author":"Mottl","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2215\/CJN.11370918","article-title":"ACCORDION: ensuring that we hear the music clearly","volume":"13","author":"Wong","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"359","DOI":"10.5543\/tkda.2019.25169","article-title":"Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: real life data from a lipid clinic cohort","volume":"48","author":"Kayikcioglu","year":"2020","journal-title":"Turk Kardiyol Dern Ars"},{"key":"B79","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijcard.2007.11.090","article-title":"Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer","volume":"133","author":"Mombelli","year":"2009","journal-title":"Int J Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2008.09.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study","volume":"204","author":"Jones","year":"2009","journal-title":"Atherosclerosis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.amjcard.2008.10.025","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia","volume":"103","author":"Goldberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10557-010-6266-4","article-title":"Efficacy and safety of rosuvastatin 5\u2005mg in combination with fenofibric acid 135\u2005mg in patients with mixed dyslipidemia - a phase 3 study","volume":"24","author":"Roth","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.amjcard.2010.05.005","article-title":"Efficacy and safety of adding fenofibrate 160\u2005mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40\u2005mg monotherapy","volume":"106","author":"Farnier","year":"2010","journal-title":"Am J Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ahj.2008.08.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study","volume":"157","author":"Mohiuddin","year":"2009","journal-title":"Am Heart J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1837004\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:30:49Z","timestamp":1780547449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1837004\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":84,"alternative-id":["10.3389\/fcvm.2026.1837004"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1837004","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1837004"}}